Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melhem Solh

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Blood Advances|August 11, 2020
Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplantScott R Solomon, Melhem Solh, Xu Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2015
Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk IndexAsad Bashey, Xu Zhang, Katelin Jackson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2016
T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor TransplantationJessica Gorgeis, Xu Zhang, Katelin Connor, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 17, 2022
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell TherapyPaolo F Caimi, Kirit M Ardeshna, Erin Reid, et al.
Leukemia & Lymphoma|February 7, 2013
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trialsMelhem Solh, Richard I Fisher, André Goy, et al.
Future Oncology (London, England)|November 12, 2024
Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 studyMehdi Hamadani, Paolo F Caimi, Brian Hess, et al.
Transplantation and Cellular Therapy|May 22, 2022
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple MyelomaScott R Solomon, Stacey Brown, Nancy Shegda, et al.
Bone Marrow Transplantation|March 11, 2018
Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or olderZain A Bashey, Xu Zhang, Stacey Brown, et al.
Bone Marrow Transplantation|December 7, 2018
Safety and efficacy of rituximab-based first line treatment of chronic GVHDScott R Solomon, Connie A Sizemore, Michelle Ridgeway, et al.
Cytotherapy|April 10, 2016
Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatmentJeremiah L Oyer, Veethika Pandey, Robert Y Igarashi, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Blood Advances|August 11, 2020
Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplantScott R Solomon, Melhem Solh, Xu Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2015
Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk IndexAsad Bashey, Xu Zhang, Katelin Jackson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2016
T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor TransplantationJessica Gorgeis, Xu Zhang, Katelin Connor, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 17, 2022
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell TherapyPaolo F Caimi, Kirit M Ardeshna, Erin Reid, et al.
Leukemia & Lymphoma|February 7, 2013
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trialsMelhem Solh, Richard I Fisher, André Goy, et al.
Future Oncology (London, England)|November 12, 2024
Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 studyMehdi Hamadani, Paolo F Caimi, Brian Hess, et al.
Transplantation and Cellular Therapy|May 22, 2022
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple MyelomaScott R Solomon, Stacey Brown, Nancy Shegda, et al.
Bone Marrow Transplantation|March 11, 2018
Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or olderZain A Bashey, Xu Zhang, Stacey Brown, et al.
Bone Marrow Transplantation|December 7, 2018
Safety and efficacy of rituximab-based first line treatment of chronic GVHDScott R Solomon, Connie A Sizemore, Michelle Ridgeway, et al.
Cytotherapy|April 10, 2016
Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatmentJeremiah L Oyer, Veethika Pandey, Robert Y Igarashi, et al.
Pageof 11